Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.36 |
| ▸ | MTOR | P42345 | 11/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393791 | 0.87 | ADORA3 (0.39) | ADORA3PIK3CAMTORLATS1MAPT | |
| SCHEMBL22101456 | 0.78 | MAPT (0.37) | MAPT | |
| SCHEMBL22101363 | 0.77 | TP53 (0.42) | MAPT | |
| SCHEMBL22393787 | 0.77 | PSMB8 (0.44) | — | |
| SCHEMBL22393789 | 0.76 | ADORA3 (0.39) | ADORA3PIK3CAMTORLATS1 | |
| SCHEMBL22101372 | 0.72 | HDAC1 (0.35) | LATS1THRBMAPT | |
| SCHEMBL22101810 | 0.71 | HDAC1 (0.34) | MAPT | |
| SCHEMBL22393662 | 0.68 | ADORA3 (0.47) | ADORA3PIK3CAMTORMAPT | |
| SCHEMBL19707373 | 0.66 | RAB9A (0.53) | CYP26A1MAPT | |
| SCHEMBL11333348 | 0.65 | ELANE (0.48) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | ADORA3 891/4885PIK3CA 2757/4885MTOR 853/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | ADORA3 891/4885PIK3CA 2757/4885MTOR 853/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | ADORA3 891/4885PIK3CA 2757/4885MTOR 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.